RSV

>

Latest News

ACIP Expands RSV Vaccine Recommendation to At‑Risk Adults Aged 50–59 Years
ACIP Expands RSV Vaccine Recommendation to At‑Risk Adults Aged 50–59 Years

April 17th 2025

The CDC advisory committee also endorsed GSK's pentavalent meningococcal vaccine.

RSV Vaccine Uptake Low Among Eligible Populations, Large-Scale Analysis Finds
RSV Vaccine Uptake Low Among Eligible Populations, Large-Scale Analysis Finds

April 9th 2025

Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose / image credit: ©New Africa/AdobeStock
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose

February 14th 2025

COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data / Image credit: ©freshidea/AdobeStock
COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data

February 3rd 2025

Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial

January 30th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.